These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31550881)

  • 1. Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation.
    Fuglestad B; Kerstetter NE; Bédard S; Wand AJ
    ACS Chem Biol; 2019 Oct; 14(10):2224-2232. PubMed ID: 31550881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMR characterization of weak interactions between RhoGDI2 and fragment screening hits.
    Liu J; Gao J; Li F; Ma R; Wei Q; Wang A; Wu J; Ruan K
    Biochim Biophys Acta Gen Subj; 2017 Jan; 1861(1 Pt A):3061-3070. PubMed ID: 27721047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.
    Silvestre HL; Blundell TL; Abell C; Ciulli A
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12984-9. PubMed ID: 23872845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R; Wang P; Wu J; Ruan K
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-Resolved and Quantitative Characterization of Very Weak Protein-Ligand Interactions.
    Fuglestad B; Kerstetter NE; Wand AJ
    ACS Chem Biol; 2019 Jul; 14(7):1398-1402. PubMed ID: 31246002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the importance of composite protein multiple ligand interactions in protein pockets.
    Tonddast-Navaei S; Srinivasan B; Skolnick J
    J Comput Chem; 2017 Jun; 38(15):1252-1259. PubMed ID: 27864975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A three-stage biophysical screening cascade for fragment-based drug discovery.
    Mashalidis EH; Śledź P; Lang S; Abell C
    Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CellFy: A Cell-Based Fragment Screen against C-Type Lectins.
    Schulze J; Baukmann H; Wawrzinek R; Fuchsberger FF; Specker E; Aretz J; Nazaré M; Rademacher C
    ACS Chem Biol; 2018 Dec; 13(12):3229-3235. PubMed ID: 30480432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR screening and hit validation in fragment based drug discovery.
    Campos-Olivas R
    Curr Top Med Chem; 2011; 11(1):43-67. PubMed ID: 20809889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment Hits: What do They Look Like and How do They Bind?
    Giordanetto F; Jin C; Willmore L; Feher M; Shaw DE
    J Med Chem; 2019 Apr; 62(7):3381-3394. PubMed ID: 30875465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of
    Nagatoishi S; Yamaguchi S; Katoh E; Kajita K; Yokotagawa T; Kanai S; Furuya T; Tsumoto K
    Bioorg Med Chem; 2018 May; 26(8):1929-1938. PubMed ID: 29510947
    [No Abstract]   [Full Text] [Related]  

  • 15. The benefits of constructing leads from fragment hits.
    Foloppe N
    Future Med Chem; 2011 Jul; 3(9):1111-5. PubMed ID: 21806375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biophysical screening for the discovery of small-molecule ligands.
    Ciulli A
    Methods Mol Biol; 2013; 1008():357-88. PubMed ID: 23729259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of 2D Difference Intensity Analysis for Chemical Library Screening by Protein-Detected NMR Spectroscopy.
    Egner JM; Jensen DR; Olp MD; Kennedy NW; Volkman BF; Peterson FC; Smith BC; Hill RB
    Chembiochem; 2018 Mar; 19(5):448-458. PubMed ID: 29239081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel NMR-Based Protocol to Screen Ultralow Molecular Weight Fragments.
    Favaro A; Sturlese M
    J Med Chem; 2024 Mar; 67(5):3874-3884. PubMed ID: 38426508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.